A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38

Li, J; Xie, Y; Zhao, P; Qin, Y; Oliver, BG; Tian, Y; Li, S; Wang, M; Liu, X

A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38

Li, J Xie, Y Zhao, P Qin, Y Oliver, BG Tian, Y Li, S Wang, M Liu, X

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Phytomedicine, 2021, 83, pp. 153475
Issue Date:: 2021-01-20

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (5.9 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Li, J
dc.contributor.author	Xie, Y
dc.contributor.author	Zhao, P
dc.contributor.author	Qin, Y
dc.contributor.author	Oliver, BG
dc.contributor.author	Tian, Y
dc.contributor.author	Li, S
dc.contributor.author	Wang, M
dc.contributor.author	Liu, X
dc.date.accessioned	2021-09-25T22:07:45Z
dc.date.available	2021-01-17
dc.date.available	2021-09-25T22:07:45Z
dc.date.issued	2021-01-20
dc.identifier.citation	Phytomedicine, 2021, 83, pp. 153475
dc.identifier.issn	0944-7113
dc.identifier.issn	1618-095X
dc.identifier.uri	http://hdl.handle.net/10453/150702
dc.description.abstract	Background Bufei Yishen formula (BYF), a traditional Chinese medicine (TCM), is an effective therapeutic strategy for patients with chronic obstructive pulmonary disease (COPD). Purpose To evaluate the efficacy of BYF and investigate its therapeutic mechanisms. Methods A total of 134 patients completed the study: 68 patients treated by BYF combined with conventional Western medicine in the trial group; and 66 patients treated using conventional Western medicine in the control group. The efficacy of BYF was evaluated by a subgroup analysis of data obtained from a four-center, open-label, randomized controlled trial of comprehensive TCM interventions. A rat model of COPD was treated with the key active molecules (KAM) of BYF for 8 weeks. An in vitro model of COPD was also treated with KAM. Results Patients treated with BYF had reduced frequency of acute exacerbation of COPD (p < 0.001) and duration (p = 0.028), dyspnea scale (p = 0.007), 6-min walking distance (p = 0.048). There were no differences observed in forced vital capacity in one second (FVC), forced expiratory volume in one second (FEV1), and FEV1 percentage of the predicted value (FEV1%). The five KAM of BYF (KAM-BYF) improved lung function, including tidal volume, minute ventilation, peak expiratory flow, FVC, FEV0.1, and FEV0.3, and pathological changes in COPD rats. Treatment with KAM-BYF markedly decreased the levels of interleukin 6 (IL6), tumor necrosis factor-α (TNF-α), matrix metalloproteinase 9 (MMP9), and MMP12 in serum and bronchial alveolar lavage fluid. In airway epithelial cells, KAM-BYF decreased the levels of TNF-α-induced IL8 and IL6. Finally, we discovered that the anti-inflammatory effects of KAM-BYF in COPD rats and BEAS-2Bs were mediated through inhibition of nuclear factor-kappaB (NF-κB) p65, c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase signaling. Conclusions BYF exerts beneficial effects in patients with COPD via inhibition of inflammation.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Phytomedicine
dc.relation.isbasedon	10.1016/j.phymed.2021.153475
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0607 Plant Biology, 1104 Complementary and Alternative Medicine, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Medicinal & Biomolecular Chemistry
dc.subject.mesh	Bronchoalveolar Lavage Fluid
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Rats, Sprague-Dawley
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	MAP Kinase Kinase 4
dc.subject.mesh	p38 Mitogen-Activated Protein Kinases
dc.subject.mesh	Tumor Necrosis Factor-alpha
dc.subject.mesh	NF-kappa B
dc.subject.mesh	Drugs, Chinese Herbal
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Down-Regulation
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Aged
dc.subject.mesh	Animals
dc.subject.mesh	Bronchoalveolar Lavage Fluid
dc.subject.mesh	Down-Regulation
dc.subject.mesh	Drugs, Chinese Herbal
dc.subject.mesh	Female
dc.subject.mesh	Humans
dc.subject.mesh	MAP Kinase Kinase 4
dc.subject.mesh	Male
dc.subject.mesh	Middle Aged
dc.subject.mesh	NF-kappa B
dc.subject.mesh	Pulmonary Disease, Chronic Obstructive
dc.subject.mesh	Rats, Sprague-Dawley
dc.subject.mesh	Treatment Outcome
dc.subject.mesh	Tumor Necrosis Factor-alpha
dc.subject.mesh	p38 Mitogen-Activated Protein Kinases
dc.title	A chinese herbal formula ameliorates COPD by inhibiting the inflammatory response via downregulation of p65, JNK, and p38
dc.type	Journal Article
utslib.citation.volume	83
utslib.location.activity	Germany
utslib.for	0607 Plant Biology
utslib.for	1104 Complementary and Alternative Medicine
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2021-09-25T22:07:42Z
pubs.publication-status	Published
pubs.volume	83

Abstract:

Background Bufei Yishen formula (BYF), a traditional Chinese medicine (TCM), is an effective therapeutic strategy for patients with chronic obstructive pulmonary disease (COPD). Purpose To evaluate the efficacy of BYF and investigate its therapeutic mechanisms. Methods A total of 134 patients completed the study: 68 patients treated by BYF combined with conventional Western medicine in the trial group; and 66 patients treated using conventional Western medicine in the control group. The efficacy of BYF was evaluated by a subgroup analysis of data obtained from a four-center, open-label, randomized controlled trial of comprehensive TCM interventions. A rat model of COPD was treated with the key active molecules (KAM) of BYF for 8 weeks. An in vitro model of COPD was also treated with KAM. Results Patients treated with BYF had reduced frequency of acute exacerbation of COPD (p < 0.001) and duration (p = 0.028), dyspnea scale (p = 0.007), 6-min walking distance (p = 0.048). There were no differences observed in forced vital capacity in one second (FVC), forced expiratory volume in one second (FEV1), and FEV1 percentage of the predicted value (FEV1%). The five KAM of BYF (KAM-BYF) improved lung function, including tidal volume, minute ventilation, peak expiratory flow, FVC, FEV0.1, and FEV0.3, and pathological changes in COPD rats. Treatment with KAM-BYF markedly decreased the levels of interleukin 6 (IL6), tumor necrosis factor-α (TNF-α), matrix metalloproteinase 9 (MMP9), and MMP12 in serum and bronchial alveolar lavage fluid. In airway epithelial cells, KAM-BYF decreased the levels of TNF-α-induced IL8 and IL6. Finally, we discovered that the anti-inflammatory effects of KAM-BYF in COPD rats and BEAS-2Bs were mediated through inhibition of nuclear factor-kappaB (NF-κB) p65, c-Jun NH2-terminal kinase (JNK), and p38 mitogen-activated protein kinase signaling. Conclusions BYF exerts beneficial effects in patients with COPD via inhibition of inflammation.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/150702